alendronate has been researched along with Gastric Ulcer in 28 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether the 10 mg dose of alendronate causes gastric ulcers." | 9.09 | Alendronate gastric ulcers. ( Graham, DY; Malaty, HM, 1999) |
| "Both alendronate sodium use and nonsteroidal anti-inflammatory drug use are associated with gastric ulcers." | 9.09 | Alendronate and naproxen are synergistic for development of gastric ulcers. ( Graham, DY; Malaty, HM, 2001) |
| " In the present study, we examined the effect of alendronate on the healing of acetic acid-induced gastric ulcers in rats and investigated the mechanism involved in this action both in vivo and in vitro using the rat gastric epithelial cell line (RGM1)." | 7.74 | Impairment of gastric ulcer healing by alendronate, a nitrogen-containing bisphosphonate, in rats. ( Aihara, E; Amagase, K; Hayashi, S; Nishikawa, K; Takeuchi, K, 2007) |
| " This study compared the incidence of gastric ulcers after treatment with risedronate, a pyridinyl bisphosphonate, or alendronate, a primary amino bisphosphonate, in healthy postmenopausal women stratified by Helicobacter pylori status." | 5.10 | 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. ( Blank, MA; Hunt, RH; Lanza, FL; Li, Z; Marshall, JK; Provenza, JM; Royer, MG; Thomson, AB, 2002) |
| "To investigate whether the 10 mg dose of alendronate causes gastric ulcers." | 5.09 | Alendronate gastric ulcers. ( Graham, DY; Malaty, HM, 1999) |
| " This study compared the incidence of gastric ulcers after treatment with risedronate, a pyridinyl bisphosphonate, and alendronate, a primary amino bisphosphonate." | 5.09 | Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. ( Blank, MA; Hunt, RH; Lanza, FL; Provenza, JM; Thomson, AB, 2000) |
| " Gastric ulcers developed in five out of 26 subjects given ASA, two out of 25 given alendronate, and none of 25 given placebo." | 5.09 | A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. ( Hunt, RH; James, C; Marshall, JK; Rainsford, KD, 2000) |
| "Both alendronate sodium use and nonsteroidal anti-inflammatory drug use are associated with gastric ulcers." | 5.09 | Alendronate and naproxen are synergistic for development of gastric ulcers. ( Graham, DY; Malaty, HM, 2001) |
| "This study investigated the use of simvastatin for the treatment of alendronate-induced gastric ulcers in rats." | 3.83 | Protective Effects of Simvastatin Against Alendronate-Induced Gastric Mucosal Injury in Rats. ( Araújo, TS; Carvalho, NS; Costa, DS; Medeiros, JV; Nicolau, LA; Silva, MM; Silva, RO; Soares, PM; Sousa, NA; Souza, LK, 2016) |
| " In the present study, we examined the effect of alendronate on the healing of acetic acid-induced gastric ulcers in rats and investigated the mechanism involved in this action both in vivo and in vitro using the rat gastric epithelial cell line (RGM1)." | 3.74 | Impairment of gastric ulcer healing by alendronate, a nitrogen-containing bisphosphonate, in rats. ( Aihara, E; Amagase, K; Hayashi, S; Nishikawa, K; Takeuchi, K, 2007) |
| " once daily for 1 week, markedly delayed the healing of acetic acid-induced gastric ulcers with the suppression of basic fibroblast growth factor (bFGF) expression." | 3.74 | Prophylactic effect of rebamipide against the irritative and healing impairment actions of alendronate in rat stomachs. ( Aihara, E; Amagase, K; Hayashi, S; Kato, S; Takeuchi, K, 2007) |
| "Male Sprague Dawley (SD) rats were used in the following two studies: (i) the effects of risedronate and alendronate on gastric potential difference (PD), gastric mucosal blood flow (GMBF) and acid back-diffusion in the stomach mounted on ex vivo chamber under urethane anesthesia and; (ii) the influence of daily treatment with these drugs on the healing of acetic acid-induced gastric ulcers was examined." | 3.72 | Mucosal irritative and healing impairment action of risedronate in rat stomachs: comparison with alendronate. ( Aihara, E; Kanatsu, K; Kato, S; Okayama, M; Takeuchi, K, 2004) |
| "Isolated case reports of gastric ulcers after alendronate sodium use raised concern about the gastroduodenal safety of daily alendronate." | 3.71 | Gastric and duodenal safety of daily alendronate. ( Andrade, SE; Beck, A; Boles, M; Buist, DS; Carey, VJ; Chan, KA; Chandler, JM; Chase, GA; Donahue, JG; Ettinger, B; Fishman, P; Goodman, M; Guess, HA; Gurwitz, JH; LaCroix, AZ; Levin, TR; Platt, R, 2002) |
| " Even when used according to manufacturer's dosing instructions alendronate should probably be used with caution." | 2.68 | Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin. ( Goodgame, R; Graham, DY; Malaty, HM, 1997) |
| "Treatment with montelukast prevented the damage as well as the changes in biochemical parameters in all tissues studied." | 1.33 | Gastroprotective effect of leukotriene receptor blocker montelukast in alendronat-induced lesions of the rat gastric mucosa. ( Ayanoğlu-Dülger, G; Cetinel, S; Cikler, E; Kapucu, C; Sener, G, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (17.86) | 18.2507 |
| 2000's | 17 (60.71) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silva, RO | 2 |
| Lucetti, LT | 1 |
| Wong, DV | 1 |
| Aragão, KS | 1 |
| Junior, EM | 1 |
| Soares, PM | 2 |
| Barbosa, AL | 1 |
| Ribeiro, RA | 1 |
| Souza, MH | 1 |
| Medeiros, JV | 2 |
| Carvalho, NS | 1 |
| Silva, MM | 1 |
| Nicolau, LA | 1 |
| Araújo, TS | 1 |
| Costa, DS | 1 |
| Sousa, NA | 1 |
| Souza, LK | 1 |
| Ohashi, Y | 1 |
| Aihara, E | 4 |
| Takasuka, H | 1 |
| Takahashi, K | 1 |
| Takeuchi, K | 6 |
| Cruz, L | 1 |
| Assumpção, E | 1 |
| Andrade, SF | 1 |
| Conrado, DJ | 1 |
| Kulkamp, IC | 1 |
| Guterres, SS | 1 |
| Pohlmann, AR | 1 |
| Naito, Y | 1 |
| Yoshikawa, T | 1 |
| Kato, S | 3 |
| Amagase, K | 4 |
| Inaba, A | 1 |
| Senta, T | 1 |
| Ishikawa, Y | 1 |
| Nukui, K | 1 |
| Murakami, T | 1 |
| Malnick, SD | 1 |
| Gottesfeld, F | 1 |
| Walpart, A | 1 |
| Keter, D | 1 |
| Lurie, Y | 1 |
| Beergabel, M | 1 |
| Thomson, AB | 3 |
| Marshall, JK | 2 |
| Hunt, RH | 3 |
| Provenza, JM | 2 |
| Lanza, FL | 2 |
| Royer, MG | 1 |
| Li, Z | 1 |
| Blank, MA | 3 |
| Lanza, F | 1 |
| Sener, G | 3 |
| Paskaloglu, K | 1 |
| Kapucu, C | 2 |
| Cetinel, S | 3 |
| Contuk, G | 1 |
| Ayanoğlu-Dülger, G | 3 |
| Kanatsu, K | 1 |
| Okayama, M | 1 |
| Cikler, E | 1 |
| Sehirli, O | 1 |
| Midillioğlu, S | 1 |
| Gedik, N | 1 |
| Parfitt, JR | 1 |
| Driman, DK | 1 |
| Hayashi, S | 2 |
| Nishikawa, K | 1 |
| Graham, DY | 4 |
| Malaty, HM | 3 |
| Goodgame, R | 1 |
| Elliott, SN | 1 |
| McKnight, W | 1 |
| Davies, NM | 1 |
| MacNaughton, WK | 1 |
| Wallace, JL | 2 |
| Rainsford, KD | 1 |
| James, C | 1 |
| Gottlieb, S | 1 |
| Donahue, JG | 1 |
| Chan, KA | 1 |
| Andrade, SE | 1 |
| Beck, A | 1 |
| Boles, M | 1 |
| Buist, DS | 1 |
| Carey, VJ | 1 |
| Chandler, JM | 1 |
| Chase, GA | 1 |
| Ettinger, B | 1 |
| Fishman, P | 1 |
| Goodman, M | 1 |
| Guess, HA | 1 |
| Gurwitz, JH | 1 |
| LaCroix, AZ | 1 |
| Levin, TR | 1 |
| Platt, R | 1 |
3 reviews available for alendronate and Gastric Ulcer
| Article | Year |
|---|---|
Gastric ulcerogenic and healing impairment actions of alendronate, a nitrogen-containing bisphosphonate - prophylactic effects of rebamipide.
Topics: Alanine; Alendronate; Animals; Anti-Ulcer Agents; Bone Density Conservation Agents; Humans; Quinolon | 2011 |
Bisphosphonate mucosal injury--the end of the story?
Topics: Alendronate; Diphosphonates; Duodenal Ulcer; Duodenum; Esophageal Diseases; Esophagus; Female; Human | 2003 |
Pathological effects of drugs on the gastrointestinal tract: a review.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Colitis; Drug-Related Side Effects | 2007 |
7 trials available for alendronate and Gastric Ulcer
| Article | Year |
|---|---|
14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
Topics: Aged; Alendronate; Analysis of Variance; Confidence Intervals; Dose-Response Relationship, Drug; Dru | 2002 |
Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin.
Topics: Adult; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Double-Blind Method; Esophagus | 1997 |
Alendronate gastric ulcers.
Topics: Adult; Alendronate; Cross-Over Studies; Double-Blind Method; Esophagus; Female; Gastric Mucosa; Huma | 1999 |
Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.
Topics: Adult; Alendronate; Duodenoscopy; Duodenum; Endoscopy; Esophagoscopy; Esophagus; Etidronic Acid; Fem | 2000 |
A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract.
Topics: Adult; Alendronate; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dinopros | 2000 |
Alendronate and naproxen are synergistic for development of gastric ulcers.
Topics: Adult; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Drug Synergism; Duo | 2001 |
Risk of ulcer soars with combination of arthritis drugs.
Topics: Administration, Oral; Adult; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheuma | 2001 |
18 other studies available for alendronate and Gastric Ulcer
| Article | Year |
|---|---|
Alendronate induces gastric damage by reducing nitric oxide synthase expression and NO/cGMP/K(ATP) signaling pathway.
Topics: Administration, Oral; Alendronate; Animals; Cyclic GMP; Dose-Response Relationship, Drug; Female; KA | 2014 |
Protective Effects of Simvastatin Against Alendronate-Induced Gastric Mucosal Injury in Rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Female; Ga | 2016 |
Antral ulcers induced by alendronate, a nitrogen-containing biphophonate, in rat stomachs - prophylactic effect of rebamipide.
Topics: Alanine; Alendronate; Animals; Anti-Ulcer Agents; Antioxidants; Bone Density Conservation Agents; Do | 2009 |
Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats.
Topics: Alendronate; Animals; Biological Availability; Bone and Bones; Bone Density; Bone Density Conservati | 2010 |
Rebamipide: a gastrointestinal protective drug with pleiotropic activities.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Alendronate; Allopurinol; Animals; Anti-Inflammatory Agents | 2010 |
Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate.
Topics: Alendronate; Animals; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Imidazoles; | 2011 |
Nonhealing gastric ulcer caused by chronic alendronate administration.
Topics: Abdominal Pain; Aged; Alendronate; Anti-Ulcer Agents; Bone Resorption; Drug Administration Schedule; | 2002 |
Octreotide ameliorates alendronate-induced gastric injury.
Topics: Administration, Oral; Alendronate; Animals; Female; Gastric Mucosa; Gastrointestinal Agents; Glutath | 2004 |
Mucosal irritative and healing impairment action of risedronate in rat stomachs: comparison with alendronate.
Topics: Acetic Acid; Alendronate; Animals; Diphosphonates; Etidronic Acid; Gastric Mucosa; Male; Rats; Rats, | 2004 |
Gastroprotective effect of leukotriene receptor blocker montelukast in alendronat-induced lesions of the rat gastric mucosa.
Topics: Acetates; Alendronate; Animals; Cyclopropanes; Female; Gastric Acidity Determination; Gastric Mucosa | 2005 |
Protective effect of taurine against alendronate-induced gastric damage in rats.
Topics: Alendronate; Animals; Antioxidants; Collagen; Gastric Mucosa; Glutathione; Humans; Lipid Peroxidatio | 2005 |
Impairment of gastric ulcer healing by alendronate, a nitrogen-containing bisphosphonate, in rats.
Topics: Acetic Acid; Alendronate; Animals; Bone Density Conservation Agents; Cells, Cultured; Cyclooxygenase | 2007 |
Prophylactic effect of rebamipide against the irritative and healing impairment actions of alendronate in rat stomachs.
Topics: Acetic Acid; Administration, Oral; Alanine; Alendronate; Animals; Anti-Ulcer Agents; Blotting, Weste | 2007 |
Alendronate induces gastric injury and delays ulcer healing in rodents.
Topics: Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Gastric Acid; Gastric Mucosa; Male; M | 1998 |
Excess gastric ulcers are associated with alendronate therapy.
Topics: Alendronate; Dose-Response Relationship, Drug; Humans; Stomach Ulcer | 1998 |
Upper gastrointestinal ulceration with alendronate.
Topics: Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Esophagus; Gastric Mucosa; Humans; St | 1999 |
Re: Lanza et al.--Endoscopic comparison of alendronate and risedronate.
Topics: Alendronate; Etidronic Acid; Gastroscopy; Humans; Risedronic Acid; Stomach Ulcer | 2001 |
Gastric and duodenal safety of daily alendronate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Cohort Studies; Duodenal Diseases; Duodenal Ulcer; Fema | 2002 |